Abstract
Aim:The aim of this pilot study was to evaluate the therapeutic and safety performance of an intramuscular treatment protocol of multidose of allogeneic adipose stem cells (ASCs) isolated, characterized, and expanded ex vivo from a healthy canine donor.Materials and Methods:Twelve dogs diagnosed with canine atopic dermatitis (CAD) were intramuscularly treated with 0.5×106 of cryopreserved ASCs from a healthy immunized young canine Ehrlichia canis free donor weekly for 6 weeks. Treatment efficacy was evaluated by the pruritus index and the CAD Lesion Index (CADLI) test. Safety and adverse effects were determined by injection site reaction, weight, blood chemistry, liver function, and whole blood count.Results:Canine ASCs obtained from a donor met the minimum qualities required for this type of cells and showed viability of 90% after thawing. The efficacy of the CADLI score and the pruritus index in 12 dogs with atopic dermatitis was statistically significant efficacy. No adverse reactions were observed at the intramuscular application site, or in relation to animal weight, blood cell populations, or liver and renal function.Conclusion:These results suggest that intramuscular administration of cryopreserved ASCs to dogs with atopic dermatitis is a promising cellular therapeutic product for the relief of the symptoms of this disease; however, the duration of the effects obtained with this dose and with other doses should be evaluated, as well as possible immune reactions. As far as we know, this is the first report of the use of multiple intramuscular doses cryopreserved ASCs to treat atopic dermatitis.
Highlights
Canine atopic dermatitis (CAD) is a common, genetically predisposed inflammatory and pruritic allergic skin disease with characteristic clinical features [1,2], having a prevalence of 20-30% [3]
No adverse reactions were observed at the intramuscular application site, or in relation to animal weight, blood cell populations, or liver and renal function. These results suggest that intramuscular administration of cryopreserved adipose stem cells (ASCs) to dogs with atopic dermatitis is a promising cellular therapeutic product for the relief of the symptoms of this disease; the duration of the effects obtained with this dose and with other doses should be evaluated, as well as possible immune reactions
As far as we know, this is the first report of the use of multiple intramuscular doses cryopreserved ASCs to treat atopic dermatitis
Summary
Canine atopic dermatitis (CAD) is a common, genetically predisposed inflammatory and pruritic allergic skin disease with characteristic clinical features [1,2], having a prevalence of 20-30% [3]. Some authors consider it to be a systemic Th2-dependent disease [10], while for others, it is primarily a chronic skin inflammation [11]. CAD is considered as an inflammatory disease associated with an aberrant Th2 pattern immune reaction [12]. For this reason, the criteria for diagnosis are based on signs established in clinically recognized guidelines [13].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
